

Supplementary Materials - Tai Chi exercise reduces circulating levels of inflammatory oxylipins in postmenopausal women with knee osteoarthritis: results from a pilot study

Table S1. Plasma oxylipins at baseline and unaffected by 8wk of Tai Chi (TC) exercise in women with osteoarthritis.

OxL	Substrate fatty acid	Baseline	8 weeks TC	p-value	Standardized difference
6-keto PGF1 α	Arachidonic acid	0.05 \pm 0.01	0.08 \pm 0.03	0.931	0.81
PGF2 α	Arachidonic acid	0.37 \pm 0.06	0.50 \pm 0.20	0.955	0.80
F2-IsoP	Arachidonic acid	1.17 \pm 0.20	1.55 \pm 0.30	0.666	1.04
15-deoxy PGJ ₂	Arachidonic acid	0.56 \pm 0.08	0.68 \pm 0.11	0.73	0.93
15-Keto PGE ₂	Arachidonic acid	0.86 \pm 0.66	2.88 \pm 0.80	0.177	1.72
TXB ₂	Arachidonic acid	5.37 \pm 1.44	4.58 \pm 0.90	0.963	-0.48
11(12)-EpETE	Eicosapentaenoic acid	1.28 \pm 0.26	0.94 \pm 0.16	0.489	-1.15
11(12)-EpETrE	Arachidonic acid	0.99 \pm 0.15	0.96 \pm 0.11	0.796	-0.19
11,12-DiHETrE	Arachidonic acid	0.78 \pm 0.13	0.73 \pm 0.09	0.931	-0.32
11-HETE	Arachidonic acid	0.66 \pm 0.09	0.68 \pm 0.10	0.863	0.20
12(13)-Ep-9-KOME	Linoleic acid	1.18 \pm 0.33	1.09 \pm 0.16	1	-0.27
12(13)-EpODE	α -Linolenic acid	0.29 \pm 0.07	0.42 \pm 0.08	0.136	1.30
12(13)-EpOME	Linoleic acid	9.36 \pm 1.21	12.70 \pm 2.41	0.453	1.24
12,13-DiHOME	Linoleic acid	9.61 \pm 1.34	11.95 \pm 2.99	1	0.71
13-HODE	Linoleic acid	23.66 \pm 2.80	27.53 \pm 5.55	0.796	0.62
13-HOTE	α -Linolenic acid	1.41 \pm 0.20	1.58 \pm 0.20	1	0.61
13-KODE	Linoleic acid	8.81 \pm 1.04	11.55 \pm 1.82	0.489	1.31
14(15)-EpETrE	Arachidonic acid	1.67 \pm 0.30	1.67 \pm 0.27	0.796	-0.02
14,15-DiHETE	Eicosapentaenoic acid	1.11 \pm 0.18	1.09 \pm 0.28	0.965	-0.04
14,15-DiHETrE	Arachidonic acid	0.88 \pm 0.12	0.85 \pm 0.11	0.757	-0.18
14-HDoHE	Docosahexaenoic acid	3.65 \pm 0.63	10.79 \pm 3.06	0.2	2.15
15(16)-EpODE	α -Linolenic acid	6.21 \pm 2.06	4.34 \pm 0.38	0.796	-0.89
15,16-DiHODE	α -Linolenic acid	29.17 \pm 8.39	17.96 \pm 3.52	0.34	-1.23
15-HEPE	Eicosapentaenoic acid	0.20 \pm 0.02	0.29 \pm 0.12	0.691	0.68
15-HETE	Arachidonic acid	1.06 \pm 0.17	1.19 \pm 0.20	0.489	0.48
15-KETE	Arachidonic acid	1.67 \pm 0.69	1.33 \pm 0.27	0.691	-0.39
17(18)-EpETE	Eicosapentaenoic acid	0.39 \pm 0.12	0.72 \pm 0.32	0.524	1.16
17,18-DiHETE	Eicosapentaenoic acid	4.14 \pm 0.71	4.29 \pm 0.96	0.93	0.12
17-HDoHE	Docosahexaenoic acid	3.59 \pm 0.85	4.42 \pm 1.55	0.931	0.47
18-HEPE	Eicosapentaenoic acid	0.01 \pm 0.00	0.02 \pm 0.01	0.161	1.24
19(20)-EpDoPE	Docosahexaenoic acid	1.29 \pm 0.41	1.27 \pm 0.19	0.662	-0.04
19,20-DiHDoPE	Docosahexaenoic acid	1.79 \pm 0.25	1.92 \pm 0.22	0.566	0.40
4-HDoHE	Docosahexaenoic acid	1.23 \pm 0.18	0.90 \pm 0.24	0.25	-1.09
5,6-DiHETrE	Arachidonic acid	0.55 \pm 0.08	0.52 \pm 0.08	0.73	-0.31
5-HEPE	Eicosapentaenoic acid	0.84 \pm 0.14	0.83 \pm 0.21	0.963	-0.06
5-HETE	Arachidonic acid	1.85 \pm 0.25	3.01 \pm 0.61	0.136	1.76

5-KETE	Arachidonic acid	2.88±0.91	1.71±0.35	0.387	-1.20
6-trans-LTB ₄	Arachidonic acid	0.07±0.03	0.29±0.14	0.354	1.95
8(9)-EpETrE	Arachidonic acid	0.68±0.17	0.57±0.17	0.815	-0.43
8,15-DiHETE	Arachidonic acid	0.48±0.11	0.31±0.08	0.19	-1.27
8,9-DiHETrE	Arachidonic acid	0.56±0.12	0.48±0.11	0.436	-0.50
8-HETE	Arachidonic acid	0.81±0.18	1.01±0.17	0.37	0.82
9(10)-EpODE	α-Linolenic acid	1.28±0.24	1.66±0.38	0.666	0.86
9(10)-EpOME	Linoleic acid	3.17±0.55	3.92±1.06	0.743	0.60
9,10-DiHODE	α-Linolenic acid	0.88±0.43	0.55±0.16	0.546	-0.73
9,10-DiHOME	Linoleic acid	11.39±2.79	8.537±2.629	0.387	-0.74
9,10-e-DiHO	Oleic acid	13.32±2.807	12.304±2.91	0.796	-0.25
9,10-EpO	Oleic acid	22.24±5.315	22.663±6.545	0.837	0.05
9,12,13-TriHOME	Linoleic acid	3.81±1.975	1.629±0.537	1	-1.07
9-HEPE	Eicosapentaenoic acid	0.33±0.119	0.356±0.161	0.833	0.13
9-HETE	Arachidonic acid	0.44±0.04	0.52±0.07	0.546	0.94
9-HODE	Linoleic acid	16.30±2.00	16.27±2.88	0.931	-0.01
9-HOTE	α-Linolenic acid	0.66±0.13	0.63±0.09	0.93	-0.18
9-KODE	Linoleic acid	4.98±0.58	4.71±0.94	0.546	-0.24
Lipoxin A4+Epi	Arachidonic acid	4.33±0.96	2.28±0.98	0.13	-1.50
Resolvin E1	Eicosapentaenoic acid	0.02±0.005	0.02±0.003	0.666	-0.84

Units are nM. Values are means ± standard error of the mean of n = 12, baseline and 8-week Tai-Chi intervention in subjects with knee osteoarthritis. *Indicates p<0.05. #Indicates 0.05<p<0.1. Other values are presented as standardized differences calculated from the difference between values of TC treatment and control, divided by the pooled SEM. DiHDoPE = dihydroxy dodecapentaenoic acid DiHODE = dihydroxy octadecadienoic acid; DiHOME = dihydroxy octadecamonoenoic acid; DiHETE = dihydroxy eicosatetraenoic acid; DiHETrE = dihydroxy eicosatrienoic acid; EpDoPE = epoxy dodecapentaenoic acid; EpO = epoxy octadecanoic acid; EpODE = epoxy octadecadienoic acid; EpOME; epoxy octadecamonoenoic acid; EpETE = epoxy eicosatetraenoic acid; EpETrE = epoxy eicosatrienoic acid; EpKOME = epoxy keto octadecamonoenoic acid; HDoHE = hydroxy dodecahexaenoic acid; HEPE = hydroxy eicosapentaenoic acid; HETE = hydroxy eicosatetraenoic acid; HODE hydroxy octadecadienoic acid; HOTE = hydroxy octadecatrienoic acid; KETE = keto eicosatrienoic acid; KODE = keto octadecadienoic acid; LT = leukotriene; PG = prostaglandin; TriHOME = trihydroxy octadecamonoenoic acid.

Table S2. Plasma lipid mediators (Means \pm Standard deviations nM), p-values, and VIP scores, in participants before and after 8wk of Tai Chi therapy. Missing values were imputed by Visit if present in >70% of subjects.

Metabolite	Units	Wk 0	Wk 8	p-value	VIP
PGE2	nM	14.8 \pm 15	2.13 \pm 1.9	0.0204	2.3963
12-HEPE	nM	0.322 \pm 0.17	1.95 \pm 2.8	0.0003	2.2923
LTB4	nM	0.0379 \pm 0.029	0.373 \pm 0.33	0.0021	2.2823
LEA	nM	4.81 \pm 1.1	3.75 \pm 1.9	0.0781	2.2789
13-HpODE screen	Unit less	0.0248 \pm 0.016	0.0177 \pm 0.02	0.0212	2.0555
8,15-DiHETE	nM	0.479 \pm 0.31	0.312 \pm 0.24	0.087	1.8553
NA-Gly	nM	1.13 \pm 0.79	0.892 \pm 1.4	0.2842	1.6954
14-HDoHE	nM	3.63 \pm 1.7	10.8 \pm 9.2	0.0153	1.5452
AEA	nM	2.68 \pm 0.87	2.1 \pm 1	0.076	1.5091
12-HETE	nM	6.24 \pm 3.2	18.5 \pm 16	0.0467	1.4971
Lipoxin A4+Epi	nM	4.04 \pm 2.7	2.58 \pm 2.7	0.0282	1.4758
NO-Gly	nM	6.17 \pm 3.8	4.41 \pm 2.5	0.1825	1.4404
Protectin DX	nM	0.163 \pm 0.18	0.397 \pm 0.25	0.1327	1.433
DHA (Area Ratio)	Unit less	5.36 \pm 4.3	5.75 \pm 3.7	0.4218	1.3926
9,10-DiHOME	nM	11.4 \pm 8.4	8.54 \pm 7.9	0.4146	1.3624
6-trans-LTB4	nM	0.0797 \pm 0.063	0.248 \pm 0.23	0.0383	1.3454
20-HETE	nM	5.47 \pm 3.1	7.38 \pm 3.5	0.0253	1.3391
9-HpODE screen	Unit less	0.0291 \pm 0.021	0.0198 \pm 0.013	0.1472	1.315
9,10-e-DiHO	nM	13.3 \pm 8.4	12.3 \pm 8.7	0.7653	1.3046
8,9-DiHETrE	nM	0.564 \pm 0.35	0.484 \pm 0.33	0.6589	1.2727
12,13-DiHODE	nM	0.812 \pm 1.1	2.37 \pm 3.2	0.0496	1.2172
EPA (Area Ratio)	Unit less	5.19 \pm 3.9	5.92 \pm 3.6	0.3802	1.1974
5-HETE	nM	1.85 \pm 0.74	3.01 \pm 1.8	0.049	1.1937
OEA	nM	10.6 \pm 4.1	8.47 \pm 2.1	0.1949	1.1667
2-OG	nM	1260 \pm 1100	1440 \pm 760	0.3698	1.1329
5,6-DiHETrE	nM	0.552 \pm 0.25	0.516 \pm 0.24	0.4909	1.1219
4-HDoHE	nM	1.23 \pm 0.54	0.899 \pm 0.72	0.2887	1.1206
DHEA	nM	1.35 \pm 0.65	1.14 \pm 0.65	0.1342	1.1051
Acetaminophen	nM	322 \pm 930	20 \pm 29	0.452	1.0398
18-HEPE	nM	0.0111 \pm 0.0092	0.0213 \pm 0.023	0.172	1.0287
ALA (Area Ratio)	Unit less	4.99 \pm 1.9	6.13 \pm 3.3	0.407	0.9908
11(12)-EpETE	nM	1.28 \pm 0.76	0.938 \pm 0.47	0.3812	0.984
Resolvin E1	nM	0.0239 \pm 0.015	0.0191 \pm 0.0086	0.4811	0.9417
6-keto PGF1a	nM	0.0526 \pm 0.016	0.0994 \pm 0.068	0.105	0.9413
19,20-DiHDoPA	nM	1.79 \pm 0.74	1.92 \pm 0.66	0.5162	0.9323

9,10-DiHODE	nM	0.881 ± 1.3	0.547 ± 0.48	0.2856	0.9209
5-KETE	nM	2.88 ± 2.7	1.71 ± 1	0.4975	0.9145
9-HEPE	nM	0.2 ± 0.24	0.299 ± 0.46	0.3843	0.9024
9-HOTE	nM	0.661 ± 0.37	0.634 ± 0.27	0.6868	0.9006
PEA	nM	6.98 ± 5.5	6.77 ± 3.6	0.9649	0.7906
13-KODE	nM	8.81 ± 3.1	11.6 ± 5.5	0.1777	0.7776
9(10)-EpODE	nM	1.28 ± 0.72	1.66 ± 1.1	0.3242	0.7595
9(10)-EpOME	nM	2.9 ± 1.7	3.92 ± 3.2	0.2505	0.7506
(1+2)-OG	nM	4340 ± 4100	3800 ± 2100	0.5695	0.7218
SEA	nM	3.86 ± 1.2	3.87 ± 1.3	0.9166	0.7128
15,16-DiHODE	nM	29.2 ± 25	18 ± 11	0.4308	0.7082
9-KODE	nM	4.98 ± 1.7	4.71 ± 2.8	0.5162	0.6951
Ibuprofen	nM	54.2 ± 55	86.2 ± 150	0.7255	0.6872
14,15-DiHETrE	nM	0.881 ± 0.34	0.853 ± 0.32	0.8595	0.677
15-deoxy PGJ2	nM	0.559 ± 0.24	0.684 ± 0.32	0.2177	0.6714
12(13)-EpODE	nM	0.288 ± 0.19	0.423 ± 0.25	0.2154	0.6671
8(9)-EpETrE	nM	0.677 ± 0.52	0.607 ± 0.47	0.854	0.6314
POEA Screen	Unit less	0.316 ± 0.13	0.276 ± 0.14	0.3617	0.6236
9,12,13-TriHOME	nM	3.81 ± 5.9	1.63 ± 1.6	0.6983	0.6139
12(13)-Ep-9-KODE	nM	1.32 ± 0.8	1.09 ± 0.47	0.4602	0.6026
12(13)-EpOME	nM	9.36 ± 3.6	12.7 ± 7.2	0.4846	0.5899
11(12)-EpETrE	nM	0.992 ± 0.45	0.957 ± 0.33	0.8915	0.5882
1-OG	nM	3080 ± 3200	2350 ± 1500	0.6803	0.5764
5-HEPE	nM	0.839 ± 0.42	0.8 ± 0.55	0.691	0.5659
9,10-EpO	nM	22.2 ± 16	25.2 ± 21	0.7096	0.5404
13-HOTE	nM	1.41 ± 0.6	1.58 ± 0.6	0.6246	0.5398
9-HODE	nM	16.3 ± 6	16.3 ± 8.6	0.8587	0.5183
15-HETE	nM	1.06 ± 0.52	1.19 ± 0.61	0.6414	0.5093
Naproxen	nM	6800 ± 11000	10600 ± 39000	0.5567	0.5056
17-HDoHE	nM	3.59 ± 2.5	4.42 ± 4.6	0.5729	0.4706
14(15)-EpETrE	nM	1.67 ± 0.89	1.67 ± 0.81	0.9767	0.4697
LA (Area Ratio)	Unit less	5.21 ± 1.5	5.9 ± 2.5	0.4929	0.4659
15(16)-EpODE	nM	6.21 ± 6.2	4.34 ± 1.1	0.9516	0.4548
2-LG	nM	1560 ± 780	1430 ± 770	0.6374	0.4503
9-HETE	nM	0.444 ± 0.13	0.523 ± 0.22	0.5307	0.4445
10-Nitrooleate	nM	5.06 ± 7.3	5 ± 5.3	0.7518	0.4136
15-KETE	nM	1.62 ± 2.1	1.33 ± 0.8	0.6766	0.3961
1-AG	nM	142 ± 130	98.4 ± 42	0.561	0.3951
TXB2	nM	4.66 ± 4.4	4.58 ± 2.7	0.9126	0.3909
17,18-DiHETE	nM	4.14 ± 2.1	4.29 ± 2.9	0.9271	0.3874
8-HETE	nM	0.81 ± 0.54	1.01 ± 0.44	0.1252	0.3666
11,12-DiHETrE	nM	0.779 ± 0.38	0.729 ± 0.27	0.7453	0.3518
(1+2)-AG	nM	245 ± 200	172 ± 74	0.5544	0.3371

14,15-DiHETE	nM	1.1 ± 0.55	1.09 ± 0.82	0.7286	0.3359
17(18)-EpETE	nM	0.365 ± 0.32	0.641 ± 0.56	0.1855	0.3172
1-LG	nM	4110 ± 1900	3430 ± 2300	0.4733	0.3062
2-AG	nM	104 ± 72	73.8 ± 39	0.438	0.2676
F2-IsoP	nM	1.17 ± 0.61	1.55 ± 0.89	0.334	0.2635
15-HEPE	nM	0.202 ± 0.071	0.286 ± 0.37	0.6906	0.263
13-HODE	nM	23.7 ± 8.4	27.5 ± 17	0.89	0.2389
AA (Area Ratio)	Unit less	5.64 ± 2.5	5.47 ± 1.9	0.8996	0.2269
αLEA	nM	0.177 ± 0.046	0.198 ± 0.13	0.8398	0.2255
11-HETE	nM	0.656 ± 0.26	0.683 ± 0.3	0.9973	0.1783
12,13-DiHOME	nM	9.61 ± 4	12 ± 9	0.9578	0.1497
(1+2)-LG	nM	5660 ± 2500	4860 ± 2700	0.5388	0.1187
EPEA Screen	nM	0.063 ± 0.051	0.0576 ± 0.035	0.9892	0.1024
PGF2a	nM	0.365 ± 0.17	0.505 ± 0.39	0.5335	0.0513

Missing values were imputed by Visit if present in >70% of subjects. Mean differences were assessed on data after normal transformation by 2-tailed t-tests. Partial least square discriminate analysis variable importance in projection scores of 3-dimensional analyses ($Q^2 = 0.64$, $r^2X = 0.36$; $r^2Y = 0.99$) are shown. Results are ranked by descending variable importance in projections (VIP) scores.

Abbreviations: 1-AG, 1-arachidonoylglycerol; 1-LG, 1-linoleoyl glycerol; 1-OG, 1-oleoyl glycerol; 2-AG, 2-arachidonoylglycerol; 2-LG, 2-linoleoyl glycerol; 2-OG, 2-oleoyl glycerol; 5-HEPE, 5-hydroxy-6E,8Z,11Z,14Z,17Z-eicosapentaenoic acid; 8,9-DiHETrE, 8,9-dihydroxy-5Z,11Z,14Z-eicosatrienoic acid; 8(9)-EpETrE, 8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid; 9(10)-EpODE, 9(10)-epoxy-12Z,15Z-octadecadienoic acid; 11,12-DiHETrE, 11,12-dihydroxy-5Z,8Z,14Z-eicosatrienoic acid; 11(12)-EpETrE, 11(12)-epoxy-5Z,8Z,14Z-eicosatrienoic acid; 12(13)-EpODE, 12(13)-epoxy-10E,15Z-octadecadienoic acid; 12-HEPE, 12-hydroxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid; 13-HODE, 13-hydroxy-9Z,11E-octadecadienoic acid; 13-HpODE, 13-hydroperoxy-9Z,11E-octadecadienoic acid; 14,15-DiHETE, 14,15-dihydroxy-5Z,8Z,11Z,17Z-eicosatetraenoic acid; 14(15)-EpETrE, 14(15)-epoxy-5Z,8Z,11Z-eicosatrienoic acid; 15(16)-EpODE, 15(16)-epoxy-9Z,12Z-octadecadienoic acid; 17,18-DiHETE, 17,18-dihydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid; 19(20)-EpDPE, 19(20)-epoxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid; αLEA, alpha-linolenoyl ethanolamide; AEA, arachidonoyl ethanolamide; AEA, anandamide; D-EA, docosatetraenoyl ethanolamide; DAGL, diacylglycerol lipase; DGLA, dihomo-gamma-linolenic acid; DGLA-EA, dihomo-gamma-linolenoyl ethanolamide; DHEA, docosahexaenoyl ethanolamide; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LEA, linoleoyl ethanolamide; OEA, oleoyl ethanolamide; PEA, palmitoyl ethanolamide; SEA, stearoyl ethanolamide.